These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17654439)

  • 1. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
    Marx N
    Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
    Grant PJ
    Diab Vasc Dis Res; 2007 Jun; 4(2):75-6. PubMed ID: 17654437
    [No Abstract]   [Full Text] [Related]  

  • 3. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
    McGuire DK
    Diab Vasc Dis Res; 2007 Jun; 4(2):77-9. PubMed ID: 17654438
    [No Abstract]   [Full Text] [Related]  

  • 4. The rosiglitazone meta-analysis.
    McCullough PA; Lepor NE
    Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
    [No Abstract]   [Full Text] [Related]  

  • 5. Rosiglitazone: a thunderstorm from scarce and fragile data.
    Mulrow CD; Cornell J; Localio AR
    Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398
    [No Abstract]   [Full Text] [Related]  

  • 6. Faster publication isn't always better.
    Fuster V; Farkouh ME
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
    [No Abstract]   [Full Text] [Related]  

  • 7. Rosiglitazone, marketing, and medical science.
    Moynihan R
    BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
    [No Abstract]   [Full Text] [Related]  

  • 8. The record on rosiglitazone and the risk of myocardial infarction.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
    [No Abstract]   [Full Text] [Related]  

  • 9. Thiazolidinediones, deadly sins, surrogates, and elephants.
    Cleland JG; Atkin SL
    Lancet; 2007 Sep; 370(9593):1103-4. PubMed ID: 17905146
    [No Abstract]   [Full Text] [Related]  

  • 10. Rosiglitazone and cardiovascular risk.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
    [No Abstract]   [Full Text] [Related]  

  • 11. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
    Erdmann E; Scherbaum WA
    MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosiglitazone and cardiovascular risk.
    Mannucci E; Monami M; Marchionni N
    N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
    [No Abstract]   [Full Text] [Related]  

  • 13. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
    Diamond GA; Bax L; Kaul S
    Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone and cardiovascular risk.
    Diamond GA; Kaul S
    N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
    Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rosigliazone meta-analysis: lessons for the future.
    Shuster JJ; Schatz DA
    Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
    [No Abstract]   [Full Text] [Related]  

  • 17. Rosiglitazone: seeking a balanced perspective.
    The Lancet
    Lancet; 2007 Jun; 369(9576):1834. PubMed ID: 17544746
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In brief: rosiglitazone (Avandia) unbound.
    Med Lett Drugs Ther; 2014 Feb; 56(1435):12. PubMed ID: 24662977
    [No Abstract]   [Full Text] [Related]  

  • 20. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.